ROLE OF HSP70 IN CYTOKINE PRODUCTION

被引:59
作者
HALL, TJ
机构
[1] Research Department, Pharmaceuticals Division, Ciba Geigy Ltd, Basel
来源
EXPERIENTIA | 1994年 / 50卷 / 11-12期
关键词
HSP70; CYTOKINES; MACROPHAGES; ANTIINFLAMMATORY DRUGS;
D O I
10.1007/BF01923460
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Interleukin-1 and tumor necrosis factor-alpha are potent, multifunctional cytokine mediators of inflammation and immune responses that are produced primarily by activated monocytes and macrophages. Three published papers by different groups have shown that heat shock and chemical stress with heavy metal salts or sulfhydryl reagents, all of which induce the expression of heat shock protein 70 (hsp70), concomitantly inhibit the production of these cytokines in human monocytes and mouse macrophages activated by lipopolysaccharide. These papers are reviewed and discussed in some detail. Other studies suggest that various anti-inflammatory drugs, including acetylsalicyclic acid, auranofin and dexamethasone, can also facilitate HSP expression in macrophages. However, while these studies are interesting, it is clear that not a great deal of work has been done and/or published in this area. Since many pharmaceutical companies are developing cytokine synthesis inhibitors as potential anti-inflammatory drugs, one aim of this article is to emphasize that understanding the molecular mechanism(s) that lead to increased HSP expression and decreased cytokine biosynthesis may assist in achieving this goal.
引用
收藏
页码:1048 / 1053
页数:6
相关论文
共 34 条
[1]   UNIQUE PROPERTIES OF AURANOFIN AS A POTENTIAL ANTIRHEUMATIC DRUG [J].
BARRETT, ML ;
LEWIS, GP .
AGENTS AND ACTIONS, 1986, 19 (1-2) :109-115
[2]  
BENSI G, 1990, CELL GROWTH DIFFER, V1, P491
[3]   THE BIOLOGY OF CACHECTIN/TNF - A PRIMARY MEDIATOR OF THE HOST RESPONSE [J].
BEUTLER, B ;
CERAMI, A .
ANNUAL REVIEW OF IMMUNOLOGY, 1989, 7 :625-655
[4]  
BUGIEL G, 1993, AUST NZ J MED, V23, P556
[5]   HEAT-SHOCK AND THE HEAT-SHOCK PROTEINS [J].
BURDON, RH .
BIOCHEMICAL JOURNAL, 1986, 240 (02) :313-324
[6]  
CARLSON RP, 1993, CURR OP INVEST DRUGS, V2, P751
[7]  
COOPER K, 1992, ANNU REP MED CHEM, V27, P209
[8]  
DINARELLO CA, 1989, CRIT REV IMMUNOL, V9, P1
[9]   BIOLOGY OF INTERLEUKIN-1 [J].
DINARELLO, CA .
FASEB JOURNAL, 1988, 2 (02) :108-115
[10]  
DINARELLO CA, 1986, CANCER RES, V46, P6236